Goldman Sachs’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-6,000
| Closed | -$327K | – | 5885 |
|
|
2018
Q3 | $327K | Buy |
+6,000
| New | +$410K | ﹤0.01% | 4677 |
|
|
2018
Q1 | – | Sell |
-40,300
| Closed | -$2.07M | – | 6588 |
|
|
2017
Q4 | $2.07M | Buy |
40,300
+38,200
| +1,819% | +$2.74M | ﹤0.01% | 3777 |
|
|
2017
Q3 | $187K | Buy |
2,100
+1,700
| +425% | +$129K | ﹤0.01% | 5792 |
|
|
2017
Q2 | $24K | Buy |
400
+300
| +300% | +$16.8K | ﹤0.01% | 6528 |
|
|
2017
Q1 | $5K | Sell |
100
-6,000
| -98% | -$356K | ﹤0.01% | 6661 |
|
|
2016
Q4 | $304K | Hold |
6,100
| – | – | ﹤0.01% | 5474 |
|
|
2016
Q3 | $366K | Sell |
6,100
-11,500
| -65% | -$663K | ﹤0.01% | 5328 |
|
|
2016
Q2 | $900K | Sell |
17,600
-38,100
| -68% | -$1.63M | ﹤0.01% | 4287 |
|
|
2016
Q1 | $1.64M | Buy |
55,700
+13,500
| +32% | +$426K | ﹤0.01% | 3661 |
|
|
2015
Q4 | $1.91M | Buy |
42,200
+36,200
| +603% | +$1.9M | ﹤0.01% | 3672 |
|
|
2015
Q3 | $250K | Buy |
6,000
+1,300
| +28% | +$67.8K | ﹤0.01% | 5783 |
|
|
2015
Q2 | $283K | Buy |
+4,700
| New | +$311K | ﹤0.01% | 5794 |
|
Goldman Sachs's ONCE Position: Q4 2019 in Review
Goldman Sachs sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 494,248 shares — an estimated $47.9M sold.
Goldman Sachs first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $129M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Goldman Sachs reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Goldman Sachs sold 494,248 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $47.9M.
- Goldman Sachs first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
- Goldman Sachs's Spark Therapeutics, Inc. Common Stock position peaked at $129M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Goldman Sachs's 13F filing for Q4 2019, filed 14 Feb 2020.